J. Statland

Eculizumab improves fatigue in refractory generalized myasthenia gravis

K. Patra, P. van Damme, M. Benatar, 2019, Quality of Life Research.

Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy

E. Bertini, B. Wong, E. Mercuri, 2020, Neuromuscular Disorders.

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

P. van Damme, M. Benatar, F. Piehl, 2019, Journal of the Neurological Sciences.

Restrictive lung involvement in facioscapulohumeral muscular dystrophy

R. Tawil, K. Eichinger, Michele A. Scully, 2014, Muscle & nerve.

‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

P. van Damme, M. Benatar, F. Piehl, 2020, Journal of Neurology.

Corrigendum to “Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy” [Neuromuscular Disorders, Vol. 30 (6) 2020, 492-502]

E. Bertini, B. Wong, E. Mercuri, 2021, Neuromuscular Disorders.